Clinical trials
Completed Observational Giant Cell Arteritis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 30 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of South Florida | 5 |
| Centre Hospitalier Universitaire Dijon | 4 |
| University of Aarhus | 3 |
| University Hospital, Brest | 2 |
| University of Pennsylvania | 2 |
| Central Hospital, Nancy, France | 1 |
| Centre Hospitalier Universitaire de Nīmes | 1 |
| Centre Hospitalier William Morey - Chalon sur Saône | 1 |
| Chugai Pharma France | 1 |
| Groupe français d'étude des Maladies Inflammatoires de loeil | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Giant Cell Arteritis | 30 |
| Takayasu Arteritis | 7 |
| Behcet Syndrome | 6 |
| Granulomatosis with Polyangiitis | 6 |
| Microscopic Polyangiitis | 6 |
| Polyarteritis Nodosa | 6 |
| Vasculitis | 6 |
| Churg-Strauss Syndrome | 5 |
| IgA Vasculitis | 5 |
| Vasculitis, Central Nervous System | 5 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.